Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

38.97 -1.50 (-3.71%)
Streaming Delayed Price Updated: 11:47 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗
A top regulator approved one of its drugs that afternoon. 
Via The Motley Fool
Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗
Via Chartmill
Corcept Therapeutics (NASDAQ:CORT) Stock Falls After Q4 Earnings Miss Estimates ↗
Via Chartmill
Topics Earnings
Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Compelling GARP Investment Case ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
What's Behind The Jump In Corcept Therapeutics Stock? ↗
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary... 
Via Benzinga
News headline image
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
Topics Credit Cards
Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗
Via Chartmill
News headline image
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst ↗
The company guided for $900 million to $1 billion in 2026 revenue. 
Via Stocktwits
News headline image
Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 11.1% year on year to $202.1 million. Its GAAP profit of $0.20 per... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Corcept (CORT) Q4 Earnings: What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗
The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 
Via Stocktwits
Topics Intellectual Property
News headline image
3 Small-Cap Stocks We Think Twice About
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
3 Cash-Producing Stocks We’re Skeptical Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Inspire Medical Systems, Astrana Health, Evolent Health, Corcept, and Centene Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
News headline image
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say ↗
As per the letter published by the FDA, the agency had alerted the company regarding its concerns for Relacorilant before. 
Via Stocktwits
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
News headline image
2 Stocks Under $50 to Target This Week and 1 We Turn Down
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day ↗
Focused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Healthcare Stock to Target This Week and 2 We Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over... 
Via StockStory
Topics Stocks
News headline image
Why Corcept (CORT) Stock Is Trading Lower Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.